296 posters, 7 videos, 13 audios, 14 topics, 10 sessions, 1,019 authors, 260 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
RCOphth Annual Congress 2026
18 - 21 May, 2026 | Manchester Central, Manchester
P193
Second- to fifth-line switching to Eylea 8mg for neovascular age-related macular degeneration and diabetic macular oedema: Real-world outcomes from a single centre.
Poster Presenter
Part of Topic
Medical retina
Background
•Eylea 8mg was licensed for use in nAMD and DMO in January 2025 in the UK(1).
•Real-world outcomes following switching in previously treated patients remain limited.
•We conducted a retrospective audit of the first 8 months to evaluate outcomes following treatment switching.
Objective
•To assess changes in treatment interval following switching to Eylea 8mg in previously treated nAMD and DMO patients.
Methodology
•Retrospective audit of all patients treated with Eylea 8mg at Gloucestershire Hospitals NHS FT (Jan–Aug 2025).
•Data extracted from Medisight electronic patient record.
•Inclusion: patients switched from anti-VEGF therapy at ≤8-week intervals.
•Pre-switch interval: time between final injection of prior therapy and first Eylea 8mg injection.
•Post-switch interval: median interval between subsequent Eylea 8mg injections.
•Patients failing to extend beyond >q8 on Eylea 8mg were switched as per local policy.
Results
•Eylea 8mg was used as a second- to fifth-line therapy, with 2–6 injections per eye during the study period.
•Overall interval increased from 6.0 to 6.5 weeks, with no change in the Eylea 2mg group and minimal increase in the Vabysmo group.
•In nAMD, interval remained unchanged in the Eylea 2mg group (n=49) and increased minimally in the Vabysmo group (n=34).
•In DMO, interval decreased slightly with Eylea 2mg (n=8) and increased with Vabysmo (n=2).
Conclusion
•Modest interval gains with Eylea 8mg likely reflect a heavily pre-treated cohort (second- to fifth-line use), (2,3) with most patients active on <8-week intervals prior to switch.
•Benefits align with PHOTON study (4) for patients with DMO, although data are limited. There may be advantage in switching to Eylea 8mg in patients with DMO previously treated with faricimab.
•Further larger scale real-world studies are needed to better understand outcomes associated with switching. Such studies are unlikely to receive industry funding and may require co-ordination from national bodies such as the Royal College of Ophthalmologists and the British and Eire Association of Medical Retina Specialists (BEAMS).